Shaghayegh Pezeshki - Department of Immunology, School of Medicine, Iran University of Medical Science, Tehran, Iran.
Payam Hashemi - School of Medicine, Tehran University of Medical Science, Tehran, Iran.
Alireza Salimi - Department of Molecular and Cellular Sciences, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Sheida Ebrahimi - Department of Genetic, Faculty of biology, Yazd University, Yazd, Iran
Mandana Javanzad - Medical Branch, Islamic Azad University, Tehran, Iran.
Amir Monfaredan - Department of Hematology, Faculty of Medicine, Tabriz Branch, Islamic Azad University, Tabriz, Iran.

Background: Prostate cancer (PC) is one of the most abundant cancers among men, and In Iran, has been responsible for ۶% of all deaths from cancer in men. NUF۲ and GMNN genes are considered as loci of susceptibility to tumorigenesis in humans. Alterations in expression of these genes have been reported in various malignancies. The aim of our study was to test whether different NUF۲ and GMNN expression levels are associated with PC incidence and hence, might be considered as new molecular tools for PC screening. Methods: Biopsy samples from ۴۰ PC patients and ۴۱ healthy Iranian men were used to determine the relative gene expression. After RNA extraction and cDNA synthesis, samples were analyzed using TaqMan Quantitative Real time PCR. Patients’ background information, included smoking habits and family histories of PC, were recorded. Stages and grades of their PC were classified by the TNM tumor, node, metastasis (TMN) staging system based on standard guidelines. Results: NUF۲ expression did not significantly differ between the groups, while GMNN expression was significantly greater in the PC specimens than in the controls. Conclusions: Regarding the significant role of GMNN in various tumor phenotypes, and its importance in PC progression, the alteration in GMNN expression in PC samples vs. controls indicate that the genetic profiling of this cancer might be considered to personalize therapy for each patient in the future.

Family history, Geminin (GMNN), Tumor staging, NUF۲, Prostate cancer.